Esperion Therapeutics (ESPR) Income from Continuing Operations (2012 - 2026)
Esperion Therapeutics (ESPR) posted Income from Continuing Operations of 26379000.0 for Q1 2026, down 142.14% on a QoQ basis from 62597000.0 in Q4 2025, and up 36.48% year-over-year from 19328464.63 in Q1 2025.
Esperion Therapeutics (ESPR) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 26379000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 36.48% year-over-year to 26379000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9183000.0 (up 91.86% YoY) and the FY2025 annual result came in at 22682000.0, up 56.17% from the prior year.
- Income from Continuing Operations was 26379000.0 for Q1 2026 at Esperion Therapeutics, down from 62597000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 62597000.0 in Q4 2025 and bottomed at 66642000.0 in Q2 2022.
- A 5-year average of 30273176.47 and a median of 41527000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 315.28% in 2025, while the deepest fall reached 171.3% in 2025.
- Esperion Therapeutics' Income from Continuing Operations stood at 56842000.0 in 2022, then decreased by 1.02% to 57424000.0 in 2023, then soared by 49.36% to 29077000.0 in 2024, then soared by 315.28% to 62597000.0 in 2025, then slumped by 142.14% to 26379000.0 in 2026.
- Business Quant data shows ESPR's Income from Continuing Operations at 26379000.0 in Q1 2026, 62597000.0 in Q4 2025, and 32010000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -26.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.38 Mn |
| Dec 31, 2025 | 62.60 Mn |
| Sep 30, 2025 | -32.01 Mn |
| Jun 30, 2025 | -13.39 Mn |
| Mar 31, 2025 | -41.53 Mn |
| Dec 31, 2024 | -29.08 Mn |
| Sep 30, 2024 | -31.11 Mn |
| Jun 30, 2024 | -11.14 Mn |
| Mar 31, 2024 | 58.25 Mn |
| Dec 31, 2023 | -57.42 Mn |
| Sep 30, 2023 | -42.53 Mn |
| Jun 30, 2023 | -51.60 Mn |
| Mar 31, 2023 | -62.99 Mn |
| Dec 31, 2022 | -56.84 Mn |
| Sep 30, 2022 | -55.78 Mn |
| Jun 30, 2022 | -66.64 Mn |
| Mar 31, 2022 | -57.05 Mn |
| Dec 31, 2021 | -69.06 Mn |
| Sep 30, 2021 | -69.40 Mn |
| Jun 30, 2021 | -43.68 Mn |